StockData
Danaher Corp logo

Danaher Corp

DHRNYSEIndustrial Instruments For Measurement, Display, and ControlFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 26, 2026Last filing: 10-Q on Jul 21, 2026Score 12/3027% above fair value
$227.97−4.26 (-1.83%)

Close on Nov 2, 2026Market cap $160.26BP/E 40.5Yield –

Danaher Cepheid Respiratory Testing Revenue by Quarter

Cepheid Respiratory Testing Revenue (GeneXpert 4-in-1 & COVID-19) ($M)

QuarterlyAnnual

Danaher Cepheid Respiratory Testing Revenue: $350M in Q3 2026, down 30.0% from a year earlier.

Latest, Q3 2026
350
Period ended Sep 30, 2026
Change on a year earlier
-30.0%
500 in Q3 2025
History
15 quarters
Since Q1 2023
Sources
9
Documents cited below

Where the Q3 2026 figure comes from

Source: Danaher IR — nongaap_2026Q3 ↗

Revenue from respiratory test cartridges run on the GeneXpert system (4-in-1 Flu A/B, RSV, SARS-CoV-2 combo and standalone COVID-19 tests); reported continuously across 15 consecutive quarters from Q1 2023 through Q3 2026 ($350M in Q3 2026; $1,900M for full-year FY2025).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCepheid Respiratory Testing Revenue (GeneXpert 4-in-1 & COVID-19) ($M)Year on yearSource
Q3 2026Sep 30, 2026350-30.0%Danaher IR — nongaap_2026Q3 ↗
Q2 2026Jun 30, 2026250-16.7%Danaher IR — nongaap_2026Q3 ↗
Q1 2026Mar 31, 2026500-23.1%Danaher IR — nongaap_2026Q3 ↗
Q4 2025Dec 31, 2025500-9.1%Danaher IR — nongaap_2026Q3 ↗
Q3 2025Sep 30, 2025500+17.6%Danaher IR — nongaap_2026Q3 ↗
Q2 2025Jun 30, 20253000.0%Danaher IR — nongaap_2026Q3 ↗
Q1 2025Mar 31, 2025650-3.7%Danaher IR — nongaap_2026Q3 ↗
Q4 2024Dec 31, 2024550-15.4%Danaher IR — supplement_2024Q4 ↗
Q3 2024Sep 30, 2024425+21.4%Danaher IR — supplement_2024Q3 ↗
Q2 2024Jun 30, 20243000.0%Danaher IR — supplement_2024Q2 ↗
Q1 2024Mar 31, 2024675+22.7%Danaher IR — supplement_2024Q1 ↗
Q4 2023Dec 31, 2023650–Danaher IR — supplement_2023Q4 ↗
Q3 2023Sep 30, 2023350–Danaher IR — supplement_2023Q3 ↗
Q2 2023Jun 30, 2023300–Danaher IR — supplement_2023Q2 ↗
Q1 2023Mar 31, 2023550–Danaher IR — supplement_2023Q1 ↗

Cite this data

StockData. (2026). Danaher Cepheid Respiratory Testing Revenue ($M), quarterly Q1 2023–Q3 2026 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/cepheid-respiratory-rev

See every metric in the Danaher KPI table. Data updated Nov 2, 2026.